📊 SGMT Key Takeaways
Is Sagimet Biosciences Inc. (SGMT) a Good Investment?
Sagimet is a development-stage pharmaceutical company with a strong balance sheet ($36.6M cash, zero debt) but severe operating losses (-$10.7M net income on only $2.0M revenue) that are deteriorating year-over-year. The company's negative free cash flow (-$8.6M) and absence of revenue traction indicate an unproven business model with estimated 4+ quarters of cash runway, making this a high-risk investment without demonstrated clinical or commercial validation.
Sagimet Biosciences Inc. Key Strengths (SGMT)
- Strong balance sheet with $36.6M cash and minimal liabilities ($7.2M total debt)
- Excellent liquidity position with 20.34x current ratio providing financial flexibility
- Low leverage (0.00x debt-to-equity) enables continued R&D investment without refinancing pressure
SGMT Stock Risks: Sagimet Biosciences Inc. Investment Risks
- Massive operating losses (-$11.7M) with only $2.0M revenue demonstrates unproven business model and no clear profitability pathway
- Deteriorating profitability metrics with net income losses worsening 12% YoY and operating margin of -585.6%
- Negative free cash flow (-$8.6M quarterly) indicates elevated burn rate relative to cash reserves with limited runway
Key Metrics to Watch
- Quarterly revenue growth trajectory and pipeline commercialization progress
- Operating cash burn rate relative to cash reserves and estimated runway
- Clinical trial advancement, regulatory approvals, and market adoption of pipeline products
Sagimet Biosciences Inc. (SGMT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 20.34x current ratio provides a solid financial cushion.
SGMT Profit Margin, ROE & Profitability Analysis
SGMT vs Healthcare Sector: How Sagimet Biosciences Inc. Compares
How Sagimet Biosciences Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sagimet Biosciences Inc. Stock Overvalued? SGMT Valuation Analysis 2026
Based on fundamental analysis, Sagimet Biosciences Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sagimet Biosciences Inc. Balance Sheet: SGMT Debt, Cash & Liquidity
SGMT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sagimet Biosciences Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.45 indicates the company is currently unprofitable.
SGMT Revenue Growth, EPS Growth & YoY Performance
SGMT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $2.0M | -$6.4M | $-0.35 |
| Q3 2023 | $2.0M | -$6.4M | $-40.34 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sagimet Biosciences Inc. Dividends, Buybacks & Capital Allocation
SGMT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sagimet Biosciences Inc. (CIK: 0001400118)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SGMT
What is the AI rating for SGMT?
Sagimet Biosciences Inc. (SGMT) has an AI grade of C with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SGMT's key strengths?
Claude: Strong balance sheet with $36.6M cash and minimal liabilities ($7.2M total debt). Excellent liquidity position with 20.34x current ratio providing financial flexibility.
What are the risks of investing in SGMT?
Claude: Massive operating losses (-$11.7M) with only $2.0M revenue demonstrates unproven business model and no clear profitability pathway. Deteriorating profitability metrics with net income losses worsening 12% YoY and operating margin of -585.6%.
What is SGMT's revenue and growth?
Sagimet Biosciences Inc. reported revenue of $2.0M.
Does SGMT pay dividends?
Sagimet Biosciences Inc. does not currently pay dividends.
Where can I find SGMT SEC filings?
Official SEC filings for Sagimet Biosciences Inc. (CIK: 0001400118) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SGMT's EPS?
Sagimet Biosciences Inc. has a diluted EPS of $-0.33.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SGMT's fundamental grade?
Based on our AI fundamental analysis in June 2026, Sagimet Biosciences Inc. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SGMT stock overvalued or undervalued?
Valuation metrics for SGMT: ROE of -10.4% (sector avg: 15%), net margin of -532.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SGMT's AI grade for 2026?
Our dual AI analysis gives Sagimet Biosciences Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SGMT's free cash flow?
Sagimet Biosciences Inc.'s operating cash flow is $-8.6M, with capital expenditures of N/A. FCF margin is -430.6%.
How does SGMT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -532.5% (avg: 12%), ROE -10.4% (avg: 15%), current ratio 20.34 (avg: 2).